SMILES string
N4(CCCC4)C(=O)c1ccc(cc1)c2cc3c(cc2)C=C(C=C(N3)N)C(=O)N(CCC)CCC
InChI
1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-19,30H,3-6,13-16,29H2,1-2H3
InChI key
CQAGPRVMJDWWEA-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Potent and selective toll-like receptor 8 (TLR8) agonist that augments the lytic function of NK cells and enhances antibody-dependent cellular cytotoxicity.
Motolimod (VTX-2337) is a potent and selective human toll-like receptor 8 (TLR8) agonist (EC50 = 100 nM; no murine TLR8-stimulating potenty) with greatly reduced TLR7 potency (EC50 >30 µM) and little activity toward TLR3/4/5/8. Motolimod induces proinflammatory mediators production in huaman PBMCs (TNFα/IL12 EC50 = 140/120 nM) by stimulating TLR8-expressing monocytes and mDCs, but not non-TLR8-expressing pDCs. Motolimod augments the lytic function of NK cells and enhances antibody-dependent cellular cytotoxicity (ADCC).
Motolimod (VTX-2337) is a potent and selective human toll-like receptor 8 (TLR8) agonist (EC50 = 100 nM; no murine TLR8-stimulating potenty) with greatly reduced TLR7 potency (EC50 >30 µM) and little activity toward TLR3/4/5/8. Motolimod induces proinflammatory mediators production in huaman PBMCs (TNFα/IL12 EC50 = 140/120 nM) by stimulating TLR8-expressing monocytes and mDCs, but not non-TLR8-expressing pDCs. Motolimod augments the lytic function of NK cells and enhances antibody-dependent cellular cytotoxicity (ADCC).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
PLoS ONE, 11(2) (2016)
Yushe Dang et al.
Journal of leukocyte biology, 103(1), 157-164 (2018-01-19)
Myeloid-derived suppressor cells (MDSCs) accumulate in tumors and the peripheral blood of cancer patients and demonstrate cancer-promoting activity across multiple tumor types. A limited number of agents are known to impact MDSC activity. TLR8 is expressed in myeloid cells. We
Hailing Lu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 18(2), 499-509 (2011-12-01)
We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its potential to improve monoclonal antibody-based immunotherapy that includes the activation of natural killer (NK) cells. HEK-TLR transfectants were used to compare the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持